Pharmaceutical Safety Review • Moderate Interaction Classification
TUDCA vs Milk Thistle (Silymarin) Prescription Drug Interactions & CYP450 Profile
Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.
Absolute Clinical Contraindications
- Complete biliary tract obstruction
- Severe gallstone impaction
- Acute cholecystitis
Reported Clinical Adverse Events
- Mild diarrhea or loose stools at TUDCA doses >1,000mg
- Mild laxative effect from silymarin
- Mild abdominal cramps
Hepatic Cytochrome P450 (CYP) & Transporter Pathways
Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:
- CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
- Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
- Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (TUDCA: approx. 3 hours (circulates via enterohepatic recycling)).